Efficacy of anti-aging products for periorbital wrinkles as measured by 3-D imaging

Background The periorbital area is a key wrinkle‐prone region, where the first signs of aging usually appear. Aims To demonstrate the ability of new anti‐aging moisturizing products to improve overall smoothness and wrinkle depth appearance in the periorbital region via the Fast Optical in vivo Topometry of Human Skin (FOITS). Methods Two double‐blind, randomized, controlled, split‐face studies (n = 42, Study 1; n = 35, Study 2) were conducted in women 30–70 years old with moderate to distinct periorbital wrinkles. Subjects applied 0.5 g of individual products to half their face twice daily for 4 weeks. Four test products containing niacinamide, the peptides Pal‐KT and Pal‐KTTKS, and carnosine were used and included a daytime SPF 30 lotion also containing antioxidants, a night cream, an eye cream also containing caffeine, and a wrinkle treatment containing retinyl propionate. The wrinkle treatment was only tested in Study 2. The FOITS technique was used to measure changes in periorbital R_a (mean roughness) and R_z (average maximum roughness) at 2 and 4 weeks. Results In Study 1, the daytime SPF 30 lotion, night cream, and eye cream significantly improved crow’s feet smoothness after 4 weeks relative to no treatment. After 4 weeks, the daytime SPF 30 lotion and night cream, but not the eye cream, were significantly better than no treatment at improving R_z. In Study 2, the night cream, eye cream, and wrinkle treatment, but not the daytime SPF 30 lotion, significantly improved both R_a and R_z after 4 weeks. To increase power and precision of estimates, a meta‐analysis was performed; the pooled data showed all three products were significantly better than no treatment at improving R_a and R_z after 4 weeks. Conclusions Four weeks of treatment with these products was shown to improve the smoothness of periorbital skin and to reduce the apparent depth of larger wrinkles.     

射频技术治疗面颈部皮肤皱纹和松弛的临床疗效观察

目的 评估射频技术治疗面颈部皮肤皱纹和松弛的疗效和安全性。 方法 30例皮肤老化志愿者，每2周使用AlumaTM FACES射频治疗仪治疗面颈部皮肤皱纹和松弛1次，共6次，分别在治疗前、治疗第4、6次时（即完成3次、5次治疗后）以及治疗结束后1个月对志愿者皮损的改善和满意度进行评价，并记录不良反应。结果 24例志愿者治疗3次后总有效率66.7%，5次后总有效率90.5%，停止治疗后1个月，总有效率94.4%。志愿者满意度评价：治疗3次后为50.0%, 5次后为90.5%，停止治疗后1个月为100%。治疗中主要不良反应为皮肤轻度紫癜。结论 射频技术治疗面颈部皮肤皱纹和松弛安全、有效。     

A pilot study evaluating the anti-aging benefits of a CO2-emitting facial mask

Background

Since 1936, injectable carboxytherapy has been used for the treatment of circulatory issues and lack of tissue trophism. In the last 25 years, it has been applied to aesthetic issues, especially those related to the signs and symptoms of skin aging. Presently, carboxytherapy is available as a combination of transcutaneous gels that produce CO₂ with benefit for atrophic skin.

Objective

The objective of this study was to investigate the efficacy and safety of a topical carboxy mask on facial photoaging after short term use of 4 weeks and long term use of 10 weeks.

Methods

The short term study was conducted for 14 days after 3 times weekly application of the facial mask for 1 h followed by a regression phase with evaluations at days 21 and 28. 11 healthy female subjects age 45–75 years were enrolled. Subjects applied the facial mask for 45 min, 3 times per week during the 2-week treatment period. The long term study was conducted for 10 weeks on 35 subjects 35–65 years with mild to moderate facial photoaging of Fitzpatrick skin types I–VI. Subjects underwent photography, elasticity, hydration, and VAS questionnaire assessments.

Results

The short term 4 week study demonstrated improvement in laser-Doppler measured blood flow and skin hydration. The long term 10 week study demonstrated improvement in firmness (16%, p = 0.001), sagging (9%, p = 0.023), and overall skin appearance (12%, p = 0.002). These findings were supported by the retraction time decrease at week 10 (−10%, p = 0.05).

Summary

The combination of two gels produced the liberation of CO₂, which improved short term skin hydration after 4 weeks of use and improved longer term skin elasticity after 10 weeks of use.     

A clinical trial comparing the safety and efficacy of a topical erythromycin-zinc formulation with a topical clindamycin formulation

One hundred three patients with acne vulgaris were randomly designated to receive either a topical formulation of erythromycin plus zinc or a topical solution of 1% clindamycin phosphate (Cleocin-T). The patients treated themselves twice daily and were examined at 3, 6, 9, and 12 weeks after the start of therapy. By week 6 the overall severity grade was consistently lower and the percent reduction of severity, papules, pustules, and total comedones was higher in the erythromycin-zinc-treated group than in the clindamycin-treated group. In the 92 patients who completed this study (48 receiving erythromycin-zinc and 44 receiving clindamycin), no serious topical or systemic side effects were reported. Two patients, one from each treatment group, suffered mild irritation. One patient was withdrawn from the erythromycin-zinc-treated group. Results of patch tests were negative. The superiority of the erythromycin-zinc formulation may be due to the increased (4%) erythromycin concentration and/or the ability of 1.2% zinc acetate to enhance the product's activity.     

Clinical efficacy and safety of topical versus oral ivermectin in treatment of uncomplicated scabies

Many medications are available for scabies treatment including oral and topical ivermectin. However, studies comparing these two forms as a scabies treatment are few. This study compares efficacy and safety of topical versus oral ivermectin as scabies treatment. The study included 62 confirmed uncomplicated scabies patients, divided into: Group I (32 patients, received topical ivermectin) and Group II (30 patients, received oral ivermectin). Patients were assessed, clinically and by KOH smear at 1, 2 and 4 weeks. Treatment was repeated after one week in patients with persistent infection. Adverse events were recorded. Most patients (87.5% and 73.5% in group I and group II respectively) were symptom free after a single treatment. A second treatment was required in 4 patients of group I and 8 patients of group II. However, 2 weeks after treatment symptoms and signs completely resolved in all cases with no recurrence at 4 weeks. This study suggests that both topical and oral ivermectin are safe and equally effective in treatment of uncomplicated scabies. Single treatment, whether topical or oral, is associated with high cure rate in a week post treatment. However, repeating treatment after one week may be required to achieve 100% cure.     

Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids

Derivatives of hydrocortisone, such as mometasone furoate, a (2′) furoate‐17 ester with chlorine substitutions at positions 9 and 21, have been designed to improve efficacy and reduce the incidence of adverse effects. An extensive literature search of MEDLINE, Embase and other databases was conducted to review the safety and efficacy of various formulations of topical mometasone furoate. Mometasone furoate exhibits high potency with greater anti‐inflammatory activity and a longer duration of action than betamethasone. In clinical trials, mometasone furoate shows comparable or significantly better efficacy, depending on the comparator, in all indications studied in both adults and children. It is well tolerated with only transient, mild to moderate local adverse effects. It is characterised by low systemic availability due to its high lipophilicity, low percutaneous absorption and rapid hepatic biotransformation, and consequently has no significant effect on the hypothalamic‐pituitary‐adrenal axis. The molecular biotransformation of mometasone furoate in the skin results in a lower affinity with dermal cells than epidermal cells, which contributes to its low atrophogenicity. Sensitisation to mometasone furoate is low. Overall, mometasone furoate is a highly efficacious potent corticosteroid with a low risk of both local and systemic adverse effects.     

Clinical efficacy and safety of a topical combination of retinaldehyde 0.1% with erythromycin 4% in acne vulgaris

The objective of this randomized, controlled, multicentre study was to assess the efficacy and safety of a topically applied retinaldehyde 0.1% gel in combination with a topical erythromycin 4% lotion for the treatment of acne vulgaris. Treatment consisted of applying either retinaldehyde or its vehicle every morning and erythromycin every evening for 8 weeks. Efficacy parameters were sequential lesion counts for papules and pustules, and a 6-point semiquantitative scale for comedones and microcysts. Safety parameters were local tolerance and adverse events. Of 74 recruited patients, 73 were appraisable for efficacy and safety. In both treatment groups, papules and pustules were reduced significantly at the end of treatment (P < 0.001), and no statistical difference was observed between the groups. Comedones and microcysts were significantly improved with retinaldehyde combined with erythromycin (P = 0.005), but not with erythromycin alone. However, no statistical difference between the groups could be demonstrated (test power, 50%). Local tolerance of the combined treatment group was very satisfactory, as only a few patients experienced local irritation. In conclusion, retinaldehyde combined with erythromycin appears to be a valuable topical therapy in polymorphic acne.     

外用西罗莫司治疗儿童浅表脉管畸形19例的临床疗效及安全性分析

目的:研究外用西罗莫司乳膏治疗儿童浅表脉管畸形的有效性与安全性。方法:采用单中心前瞻性设计,纳入2019年9月至2020年9月就诊于首都医科大学附属北京儿童医院皮肤科脉管性疾病专业门诊的浅表脉管畸形患儿,予0.1%西罗莫司乳膏外用,通过影像学、皮肤镜、主观评定等指标,根据国际通用四级分类法评估疗效,同时监测用药期间的不...     

In vitro and in vivo efficacy of a cosmetic product formulated with new lipid particles for the treatment of aged skin

Background

The cumulative oxidative damage causes an acceleration in the skin aging.

Objectives

To evaluate the ability of a new patented matrix of lipid particles (SIREN CAPSULE TECHNOLOGY™) to have superior anti-aging properties due to its high sensitivity to reactive oxygen species (ROS), testing its efficacy versus free or encapsulated vitamins.

Methods

An in vitro study was conducted to evaluate the protective effects of lipid particles using menadione as an enhancer of oxidative stress. Subsequently, in vivo studies evaluated skin hydration, skin barrier function, and smoothness and wrinkle depth. For this purpose, gels containing free or encapsulated vitamins were used as controls.

Results

In vitro, the SIREN CAPSULE TECHNOLOGY™ gel shows inhibitory activity against ROS production through menadione induction. In fact, at both tested concentrations, ROS production is lower than in the control samples (placebo, free vitamins, encapsulated vitamins). In vivo, the net effect of SIREN CAPSULE TECHNOLOGY™ gel versus the others permitted to conclude that lipid particles exert a higher skin moisturizing effect (20.17%) and a stronger effect in reducing transepidermal water loss (−16.29%) after 4 weeks of treatment. As for surface analysis, a gel based on SIREN CAPSULE TECHNOLOGY™ improves the skin texture in a similar way than gel containing encapsulated vitamins (Ra and Rz variations in 4 weeks).

Conclusions

SIREN CAPSULE TECHNOLOGY™ represents an advance and a successful strategy to develop cosmetic products for the treatment of skin conditions associated with an accumulation of ROS. SIREN CAPSULE TECHNOLOGY™ represents a result-oriented breakthrough in the effective delivery of active ingredients to the skin.     

The efficacy of a new topical treatment for psoriasis: Mirak

Background A new natural product for the treatment of psoriasis has recently become available in many European countries: Mirak. The Mirak Home Care Packs consist of natural spring water, volcanic earth and vitamin E cream. Recently, the efficacy of Mirak has come into question. As this treatment is used by many psoriasis patients in Europe, it is important for dermatologists to be informed about the clinical effects of the therapy.
Aim To evaluate the efficacy and side effects of the Mirak Home Care Packs.
Methods By means of a placebo-controlled left/right comparison, both clinical and histological parameters were evaluated during 6 weeks of treatment.
Results The reduction in induration was significantly greater in the Mirak-treated lesions than in the lesions treated with a placebo. A reduction in desquamation was found in both treatments; the difference between the treatments was not statistically significant. A decrease in number of proliferative cells in the Mirak-treated lesions was seen, but the difference with placebo-treated lesions was not significant. The other investigated parameters did not change during treatment. No side effects were seen.
Conclusions The Mirak Home Care Pack induces a modest therapeutic effect compared to placebo treatment, without significant side effects. Treatment with the Mirak Home Care Packs alone will probably not be able to compete with the already existing treatments for psoriasis.     

Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women

Background: Two drugs which are approved for the treatment of androgenetic alopecia in women in Germany were compared with regard to their influence on hair growth. Patients and Methods: Patients were randomized to group I (n = 52) who used 2% minoxidil solution twice daily for a period of 12 months or to group II (n = 51) who used 0.025% alfatradiol solution once daily for 6 months and were then switched to 2% minoxidil solution for months 7–12. Changes in hair growth parameters were determined using the TrichoScan. Results:Topical treatment with 2% minoxidil solution for 6 months resulted in a significant increase of cumulative hair thickness (p < 0.0001) and absolute hair density (p ≤ 0.0025), whereas these parameters of hair growth remained nearly unchanged after 6 months of treatment with alfatradiol solution. Evaluation of the same parameters from month 7 to month 12 demonstrated that 12 months minoxidil treatment resulted in an increasing stabilization (group I). After the alfatradiol→minoxidil switch in group II a significant increase in cumulative hair thickness (p < 0.0001) and absolute hair density (p < 0.0001) was achieved. Both study medications were well tolerated. Conclusions: Treatment with minoxidil can induce an increase in hair density and hair thickness,whereas treatment with alfatradiol results in deceleration or stabilization of hair loss.     

Improvements in skin quality parameters in postmenopausal participants after use of topical growth factor serum

Background

Photodamage can induce skin aging processes that can be particularly concerning for postmenopausal women. Growth factors from hypoxic human fibroblast-conditioned media have demonstrated improvements in skin quality parameters.

Aims

The aim of the study was to assess efficacy and tolerability of topical combination-treatment hypoxic growth factor serum (TNS A+) in postmenopausal women with moderate to severe facial photodamage.

Patients/Methods

In this 12-week, open-label, single-center study, participants used TNS A+ serum twice daily. Postmenopausal women (40–65 years of age) with Fitzpatrick skin types I–VI and modified Griffiths scale scores 4–9 were eligible. Clinical and participant-reported assessments were evaluated at Weeks 6 and 12. Statistical significance was defined as p ≤ 0.05.

Results

There were 17 enrolled participants. TNS A+ treatment demonstrated significant improvements from baseline in fine lines and wrinkles in periocular, forehead, and cheek areas at Week 12 and the perioral area at Weeks 6 and 12. Significant improvements from baseline in coarse lines and wrinkles were observed for the perioral area at Week 12 and periocular and cheek areas at Weeks 6 and 12. Improvements in overall photodamage, skin tone evenness, and tactile roughness were significantly greater at Weeks 6 and 12 versus baseline. Most participants reported TNS A+ made their skin look and feel smooth, soft, and rejuvenated; improved skin radiance; made lines and wrinkles less apparent; and improved skin texture. No treatment-related adverse events were reported.

Conclusions

The TNS A+ regimen was well tolerated and provided significant improvements in skin quality in postmenopausal women with moderate to severe facial photodamage.